Annex to press release 2 April 2015

	2014				
amounts in € million	Q1	Q2	Q3	Q4	Year
Nutrition					
Net sales	1,047	1,073	1,091	1,124	4,335
EBITDA	203	222	225	200	850
EBIT	143	165	163	125	596
Performance Materials					
Net sales	589	615	638	618	2,460
EBITDA	71	85	87	80	323
EBIT	43	55	55		204
Innovation Center					
Net sales	34	38	40	42	154
EBITDA	-6	-5	-4	-3	-18
EBIT	-14	-12	-10		
		. –			
Corporate Activities	11				
Net sales	22	28	25	27	102
EBITDA	-29	-38	-27	-23	-117
EBIT	-39	-51	-39		-168
		01	07		100
Continuing Operations					
Net sales	1,692	1,754	1,794	1,811	7,051
EBITDA	239	264	281	254	1,038
EBIT	133	157	169		587
	155	157	109	120	507
Discontinued					
Net sales	606	534	529	563	2,232
EBITDA	31	29	34	34	128
EBIT	11	8	14		30
		0	14	-5	50
Total DSM					
Net sales	2,298	2,288	2,323	2,374	9,283
EBITDA	270	293	315		1,166
EBIT	144	165	183		617
		100		120	017
Kaufiguras (continuing anarctions, hofers avaantional items)					
Key figures (continuing operations, before exceptional items)					
Capay cash	11				1-1
- Capex cash	11				451
- Operating working capital	11				1,903
- OWC / net sales - ROCE	11				26.3%
- RUCE					8.2%
EDIT (continuing operations, before executional items)	11				F07
EBIT (continuing operations, before exceptional items)	11				587
Finex	11				-102
Tax	11				-84
Result associates	11				8
Group net profit	11				409
Net profit non-controlling interests	11				-5
Net profit attributable to shareholders Kon. DSM NV					414
These comparative figures reflect the reclassification of the Polymer	DISCLAIMER				
Intermediates cluster and the DSM Composite Resins business group to	performance and p	osition. Such stateme	nts are based on cur	respect to DSM's futu rent expectations, est	imates and
discontinued operations after the announced partnership for these	projections of DSM	and information curr	ently available to the	e company. Examples	of forward-looking

Intermediates cluster and the DSM Composite Resins business group to discontinued operations after the announced partnership for these businesses with CVC Capital Partners (CVC). DSM's Corporate Activities are also restated, since DSM's 65% stake in Sitech Services will be transferred as a result of the partnership with CVC. The restatement also reflects the sale of DSM Synres to Standard Investment and Euroresins to Cathay Investments



This document may contain forward-looking statements with respect to DSM's future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. Examples of forward-looking statements include statements made or implied about the company's strategy, estimates of sales growth, financial results, cost savings and future developments in its existing businesses as well as the impact of future acquisitions, and the company's financial position. These statements can be management estimates based on information provided by specialized agencies or advisors. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause the company's actual performance and position to differ materially from these statements. These factors include, but are not limited to, macro-economic, market and business trends and conditions, (low-cost) competition, legal claims, the company's ability to protect intellectual property, changes in legislation, changes in exchange and interest rates, changes in tax rates, pension costs, raw material and energy prices, employee costs, the implementation of the company's ability to identify develop and successfully commercialize new products, markets or technologies, economic and/or political changes and other developments in countries and markets in which DSM operates. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the Risk Management chapter of DSMs integrated Annual Report 2014. As a result, DSM's actual future performance, position and/or financial results may differ materially from the plane, goals and expectations set forth in such forward looking statements. DSM has no obligation to update the statements contained in this document, unless required by law.